1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lei T, Chen WQ, Zhang SW, Lei TH, Ying Q,
He ZY and Wang XH: Prevalence trend of colorectal cancer in 10
cities and counties in China from 1988 to 2002. Zhonghua Zhong Liu
Za Zhi. 31:428–433. 2009.in Chinese. PubMed/NCBI
|
3
|
de Krijger I, Mekenkamp LJ, Punt CJ and
Nagtegaal ID: MicroRNAs in colorectal cancer metastasis. J Pathol.
224:438–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Martìn-Padura I, Lostaglio S, Schneemann
M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A,
Ruco L, Villa A, et al: Junctional adhesion molecule, a novel
member of the immunoglobulin superfamily that distributes at
intercellular junctions and modulates monocyte transmigration. J
Cell Biol. 142:117–127. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Aurrand-Lions M, Johnson-Leger C, Wong C,
Du Pasquier L and Imhof BA: Heterogeneity of endothelial junctions
is reflected by differential expression and specific subcellular
localization of the three JAM family members. Blood. 98:3699–3707.
2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Shin K, Fogg VC and Margolis B: Tight
junctions and cell polarity. Annu Rev Cell Dev Biol. 22:207–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Palmeri D, van Zante A, Huang CC,
Hemmerich S and Rosen SD: Vascular endothelial junction-associated
molecule, a novel member of the immunoglobulin superfamily, is
localized to intercellular boundaries of endothelial cells. J Biol
Chem. 275:19139–19145. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Aurrand-Lions M, Duncan L, Ballestrem C
and Imhof BA: JAM-2, a novel immunoglobulin superfamily molecule,
expressed by endothelial and lymphatic cells. J Biol Chem.
276:2733–2741. 2001. View Article : Google Scholar
|
9
|
Luissint AC, Nusrat A and Parkos CA:
JAM-related proteins in mucosal homeostasis and inflammation. Semin
Immunopathol. 36:211–226. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Brambilla D and Fais S: The Janus-faced
role of ezrin in ‘linking’ cells to either normal or metastatic
phenotype. Int J Cancer. 125:2239–2245. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Crnic I and Christofori G: Novel
technologies and recent advances in metastasis research. Int J Dev
Biol. 48:573–581. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Doñate C, Ody C, McKee T, Ruault-Jungblut
S, Fischer N, Ropraz P, Imhof BA and Matthes T: Homing of human B
cells to lymphoid organs and B-cell lymphoma engraftment are
controlled by cell adhesion molecule JAM-C. Cancer Res. 73:640–651.
2013. View Article : Google Scholar
|
14
|
Liang TW, Chiu HH, Gurney A, Sidle A,
Tumas DB, Schow P, Foster J, Klassen T, Dennis K, DeMarco RA, et
al: Vascular endothelial-junctional adhesion molecule (VE-JAM)/JAM
2 interacts with T, NK, and dendritic cells through JAM 3. J
Immunol. 168:1618–1626. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ludwig RJ, Zollner TM, Santoso S, Hardt K,
Gille J, Baatz H, Johann PS, Pfeffer J, Radeke HH, Schön MP, et al:
Junctional adhesion molecules (JAM)-B and -C contribute to
leukocyte extravasation to the skin and mediate cutaneous
inflammation. J Invest Dermatol. 125:969–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Arcangeli ML, Frontera V, Bardin F,
Thomassin J, Chetaille B, Adams S, Adams RH and Aurrand-Lions M:
The Junctional Adhesion Molecule-B regulates JAM-C-dependent
melanoma cell metastasis. FEBS Lett. 586:4046–4051. 2012.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Hajjari M, Behmanesh M, Sadeghizadeh M and
Zeinoddini M: Junctional adhesion molecules 2 and 3 may potentially
be involved in progression of gastric adenocarcinoma tumors. Med
Oncol. 30:3802013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Meguenani M, Miljkovic-Licina M, Fagiani
E, Ropraz P, Hammel P, Aurrand-Lions M, Adams RH, Christofori G,
Imhof BA and Garrido-Urbani S: Junctional adhesion molecule B
interferes with angiogenic VEGF/VEGFR2 signaling. FASEB J.
29:3411–3425. 2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Reynolds LE, Watson AR, Baker M, Jones TA,
D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S,
Rodriguez-Manzaneque JC, Martino-Echarri E, et al: Tumour
angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.
Nature. 466:3982010. View Article : Google Scholar
|
20
|
Kok-Sin T, Mokhtar NM, Ali Hassan NZ,
Sagap I, Rose IM, Harun R and Jamal R: Identification of diagnostic
markers in colorectal cancer via integrative epigenomics and
genomics data. Oncol Rep. 34:22–32. 2015.PubMed/NCBI
|
21
|
Bujko M, Kober P, Mikula M, Ligaj M,
Ostrowski J and Siedlecki JA: Expression changes of cell-cell
adhesion-related genes in colorectal tumors. Oncol Lett.
9:2463–2470. 2015.PubMed/NCBI
|
22
|
Bujko M, Kober P, Mikula M, Ligaj M,
Ostrowski J and Siedlecki JA: Expression changes of cell-cell
adhesion-related genes in colorectal tumors. Oncol Lett.
9:2463–2470. 2015.PubMed/NCBI
|
23
|
Zhang J, Huang JY, Chen YN, Yuan F, Zhang
H, Yan FH, Wang MJ, Wang G, Su M, Lu G, et al: Whole genome and
transcriptome sequencing of matched primary and peritoneal
metastatic gastric carcinoma. Sci Rep. 5:137502015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Overall CM and López-Otín C: Strategies
for MMP inhibition in cancer: Innovations for the post-trial era.
Nat Rev Cancer. 2:657–672. 2002. View
Article : Google Scholar : PubMed/NCBI
|
25
|
Chakraborti S, Mandal M, Das S, Mandal A
and Chakraborti T: Regulation of matrix metalloproteinases: An
overview. Mol Cell Biochem. 253:269–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
26
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in
human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
|
27
|
Frewer KA, Sanders AJ, Owen S, Frewer NC,
Hargest R and Jiang WG: A role for WISP2 in colorectal cancer cell
invasion and motility. Cancer Genomics Proteomics. 10:187–196.
2013.PubMed/NCBI
|
28
|
Arnold S, Mira E, Muneer S, Korpanty G,
Beck AW, Holloway SE, Mañes S and Brekken RA: Forced expression of
MMP9 rescues the loss of angiogenesis and abrogates metastasis of
pancreatic tumors triggered by the absence of host SPARC. Exp Biol
Med (Maywood). 233:860–873. 2008. View Article : Google Scholar
|
29
|
Belotti D, Paganoni P, Manenti L, Garofalo
A, Marchini S, Taraboletti G and Giavazzi R: Matrix
metalloproteinases (MMP9 and MMP2) induce the release of vascular
endothelial growth factor (VEGF) by ovarian carcinoma cells:
Implications for ascites formation. Cancer Res. 63:5224–5229.
2003.PubMed/NCBI
|
30
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al:
Matrix metalloproteinase-9 triggers the angiogenic switch during
carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
31
|
Kim HJ, Park CI, Park BW, Lee HD and Jung
WH: Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal
carcinoma in situ and invasive ductal carcinoma of the breast.
Yonsei Med J. 47:333–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
32
|
Kondratiev S, Gnepp DR, Yakirevich E, Sabo
E, Annino DJ, Rebeiz E and Laver NV: Expression and prognostic role
of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in
sinonasal and oral malignant melanomas. Hum Pathol. 39:337–343.
2008. View Article : Google Scholar
|
33
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
34
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|